Good health being the prime concern, we bring forth hygienic collection of Yashiketin that is an analgesic and antipyretic medicine. This is effective in nature and brings down the high fever into normal. They are used as pain relievers without causing anesthesia. We offer them in different doses and get readily dissolved in blood stream. Each injection constitutes 30 mg per mL of Ketorolac Tromethamine that is a member of pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs).
- Each ml contains: ketorolac tromethamine USP 30 mg, excipients q.
- Analgesic and antipyretic. Ketorolac Tromethamine is a member of
the pyrrolo-pyrrole group of non-steroidal anti-inflammatory drugs
- Yashiketin injection is indicated for the short-term ( ≤ 5 days)
management of moderately severe acute pain that requires analgesia
at the opioid level, usually in a postoperative setting. Ketorolac
tromethamine is not indicated for use in pediatric patients and it
is NOT indicated for minor or chronic painful conditions. Increasing
the dose of ketorolac tromethamine beyond the label recommendations
will not provide better efficacy but will increase the risk of
developing serious adverse events.
|Dosage and administration:
- Multiple-dose treatment (IV / IM) in adults patients <
65 years of age: The recommended dose is 30 mg ketorolac
tromethamine injection every 6 hours. The maximum daily dose should
not exceed 120 mg.
- Single-dose treatments (IV / IM) in adults patients ≥ 65 years of age or renally impaired and/or less than 50 kg (110 lbs) of body weight: One dose of 15 to 30 mg.
- Ketorolac tromethamine is a non-steroidal anti-inflammatory drug
(NSAID) that exhibits analgesic activity in animal models. Ketorolac
tromethamine inhibits synthesis of prostaglandins and may be
considered a peripherally acting analgesic. The biological activity
of ketorolac tromethamine is associated with the S-form. Ketorolac
tromethamine possesses no sedative or anxiolytic properties. The
peak analgesic effect of ketorolac tromethamine occurs within 2 to 3
- Administration of Ketorolac Tromethamine Injections may cause
adverse reactions as G.I. ulceration, bleeding and perforation,
nausea, dyspepsia, gastrointestinal pain, diarrhea, constipation,
flatulence, gastrointestinal fullness, vomiting, stomatitis,
gastritis, rectal bleeding, eructation, anorexia, increased
appetite, postoperative bleeding, acute renal failure, liver
failure, edema, hypertension, pruritus, rash, purpura, headache,
drowsiness, dizziness, sweating, tremors, abnormal dreams,
hallucinations, euphoria, extrapyramidal symptoms, vertigo,
paresthesia, depression, insomnia, nervousness, excessive thirst,
dry mouth, abnormal thinking, inability to concentrate,
hyperkinesis, stupor, weight gain, fever, infections, asthenia,
palpitation, pallor, syncope, urticaria.
- Yashiketin injection is a non-steroidal anti-inflammatory drug
(NSAID) and should not be used to exceed more than 5 days in adults.
The most serious risks associated with ketorolac tromethamine are
gastrointestinal (GI) effects such as risk of GI ulceration,
bleeding and perforation, hemorrhage, anaphylactoid reactions,
impaired renal function, fluid retention, edema, retention of NaCl,
oliguria, elevations of serum urea nitrogen and creatinine
- Yashiketin Injection should be used with caution in patients with
impaired hepatic function or a history of liver disease and
hemostasis. The administration of ketorolac tromethamine to patients
taking anticoagulants should be done extremely cautiously, and
patients should be closely monitored.
- Ketorolac Tromethamine Injections reduces the diuretic response to
furosemide. Concomitant of ketorolac tromethamine and probenecid is
contraindicated. Do not mix ketorolac tromethamine and morphine in
the same syringe.
- Yashiketin injection is contraindicated in patients
- With active peptic ulcer disease, recent gastrointestinal
bleeding or perforation and a history of peptic ulcer disease or
- With advanced renal impairment or in patients at risk for renal
failure due to volume depletion
- With labor and delivery because, through its prostaglandin
synthesis inhibitory effect, it may adversely affect fetal
circulation and inhibit uterine contractions, thus increasing the
risk of uterine hemorrhage
- As nursing mothers because of the potential adverse effects of
prostaglandin-inhibiting drugs on neonates
- With previously demonstrated hypersensitivity to ketorolac
tromethamine, or allergic manifestations to aspirin or other
non-steroidal anti-inflammatory drugs (NSAIDs).
- As prophylactic analgesic before any major surgery and is
contraindicated intra-operatively when hemostasis is critical
because of the increased risk of bleeding.
- With suspected or confirmed cerebrovascular bleeding, hemorrhagic
diathesis, incomplete hemostasis and those at high risk of bleeding
- Currently receiving ASA or NSAIDs because of the cumulative risks
of inducing serious NSAID- related adverse events
- For neuraxial (epidural or intrathecal) administration due to its
alcohol content with the concomitant use of probenecid
- Symptoms following acute NSAIDs overdoses are usually limited to
lethargy, drowsiness, nausea, vomiting and epigastric pain which are
generally reversible with supportive care. Gastrointestinal bleeding
can occur. Hypertension, acute renal failure, respiratory depression
and coma may occur, but are rare. Anaphylactoid reactions may occur
following an overdose with therapeutic ingestion of NSAIDs. Patients
should be managed by symptomatic and supportive care following a
NSAIDs overdose. There are no specific antidotes. Emesis and/or
activated charcoal and/or osmotic cathartic may be indicated in
patients seen within 4 hours of ingestion with symptoms or following
a large oral overdose (5 to 10 times the usual dose). In controlled
overdosage, daily doses of 360 mg of ketorolac tromethamine
injection given for five (5) days (three times the highest
recommended dose), may cause abdominal pain and peptic ulcers which
can heal after discontinuation of dosing. Metabolic acidosis may
occur following intentional overdosage. Single overdoses of
ketorolac tromethamine may cause abdominal pain, nausea, vomiting,
hyperventilation, peptic ulcers and/or erosive gastritis and renal
dysfunction which can be resolved after discontinuation of dosing.
Dialysis does not significantly clear ketorolac tromethamine from
the blood stream.
- 10 ampoules of 1-ml in a plastic tray and each tray packed in a
- Store between temperature 8℃ to 25℃
- Protect from light
- Keep out of the reach of children